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Introduction—Autoinflammatory diseases can cause irreversible tissue damage due to systemic
inflammation. Recently, the Autoinflammatory Disease Damage Index (ADDI) was developed.
The ADDI is the first instrument to quantify damage in familial Mediterranean fever, cryopyrin
associated periodic syndromes, mevalonate kinase deficiency and tumour necrosis factor receptor
associated periodic syndrome. The aim of this study was to validate this tool for its intended use in
a clinical/research setting.
Methods—The ADDI was scored on paper clinical cases by at least three physicians per case,
independently of each other. Face and content validity were assessed by requesting comments
on the ADDI. Reliability was tested by calculating the intraclass correlation coefficient (ICC)
using an ‘observer-nested-within-subject’ design. Construct validity was determined by correlating
the ADDI score to the Physician Global Assessment (PGA) of damage and disease activity.
Redundancy of individual items was determined with Cronbach’s alpha.
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Results—The ADDI was validated on a total of 110 paper clinical cases by 37 experts in
autoinflammatory diseases. This yielded an ICC of 0.84 (95% CI 0.78 to 0.89). The ADDI
score correlated strongly with PGA-damage (r=0.92, 95% CI 0.88 to 0.95) and was not strongly
influenced by disease activity (r=0.395, 95% CI 0.21 to 0.55). After comments from disease
experts, some item definitions were refined. The interitem correlation in all different categories
was lower than 0.7, indicating that there was no redundancy between individual damage items.
Conclusion—The ADDI is a reliable and valid instrument to quantify damage in individual
patients and can be used to compare disease outcomes in clinical studies.
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INTRODUCTION
Autoinflammatory diseases (AID) are characterised by seemingly unprovoked, recurrent
episodes of inflammation caused by activation of the innate immune system. The four
most common monogenic AIDs are cryopyrin-associated periodic syndromes (CAPS),
tumour necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase
deficiency (MKD) and familial Mediterranean fever (FMF).12 Chronic inflammation in
AIDs may cause irreversible damage in multiple organ systems, such as visual loss,
deafness, joint restriction and amyloidosis.3
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Even though targeted therapy for these AIDs has become available,4–6 permanent damage
may still accumulate before diagnosis or start of therapy. Furthermore, the majority of
studies on new biological therapies for AIDs are recently initiated, with limited follow-up,
hence the potency of these drugs to prevent or stop the development of damage is not
yet known.378 The Autoinflammatory Disease Damage Index (ADDI) has been developed
to enable assessment of the long-term burden of AIDs in a standardised manner, as a
comprehensive tool measuring damage in patients with AIDs.5 Although developed for the
four main monogenic AIDs, the ADDI may potentially also be useful in other diseases with
autoinflammatory features.910
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To properly validate a damage index such as the ADDI, several aspects are important:
reliability, content validity, face validity, criterion validity and construct validity.11 A reliable
index means that for a given patient, different observers will give the same score; this can
be assessed by calculating the interobserver variability (intraclass correlation coefficient,
ICC). Content validity tests whether the content of the index truthfully reflects the subject
the index applies to. Face validity is the subjective impression whether a test measures
the intended phenomenon. Criterion validity tests whether an index is as good as the gold
standard. Construct validity consists of convergent and discriminant validity: convergent
validity determines whether an index correlates to a similar index (eg, whether the ADDI
correlates to other indices of damage or impairments in daily living), whereas discriminant
validity determines whether the index is different from a dissimilar index (eg, the ADDI
should not correlate with indices of disease activity).
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Continuously during development and validation of the ADDI, content validity, face validity
and adherence to the OMERACT principles (truth, discrimination and feasibility) were
assessed.12–14 As a reference standard for disease damage in AIDs is lacking, criterion
validity cannot be determined. Physician Global Assessment (PGA) of damage can be
considered the best alternative for a gold standard, but it is not a validated measure.
Therefore, we decided to use the PGA-damage to assess construct validity rather than
criterion validity. Hence, in this study we aimed to investigate the reliability and construct
validity, using paper clinical cases of patients with FMF, CAPS, TRAPS and MKD,
designed to ensure that all the damage items were adequately covered.

Ann Rheum Dis. Author manuscript; available in PMC 2021 September 02.

ter Haar et al.

Page 3

Author Manuscript

METHODS
Development of the validation plan
Together with an experienced methodologist (HvS), a validation plan was developed. Paper
clinical cases were based on real patient data, but modified to protect patient privacy and
to ensure that all damage items would be sufficiently represented and different degrees of
damage could be tested. Using a pilot with a limited number of cases and expert participants,
a preliminary ICC was determined and the final number of cases required for the validation
was calculated. All expert physicians who participated in the development of the ADDI (top
40 enrollers in the Eurofever Registry and nine experts from the Americas) were invited to
participate in the validation process. One expert involved in the development of paper cases
(JF) did not take part in the scoring.
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Development of the cases
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The cases for validation of the ADDI were derived from anonymised clinical data of patients
with confirmed FMF, CAPS, TRAPS and MKD included in the European-based online
Eurofever Registry.1516 All physicians involved in the Eurofever project (Executive Agency
for Health and Consumers, Project No 2007332) were asked to complete follow-up data on
patients they had entered in the registry. The registry collects detailed information on all
potential organ involvement as well as general features of AIDs. To cover a wide case mix,
expert physicians from the Americas were asked to submit their anonymous patient data
using a preformed template. The patient information retrieved from the Eurofever Registry
and American cases served as a resource for paper clinical case scenarios. Cases were
modified to ensure that each ADDI item was represented at least four times. Precautions
were made to provide a similar number of cases for each disease and to have cases
with different grades of disease activity and damage. All paper cases were checked for
comprehensiveness and realistic character by one expert (JF).
Case distribution
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The case summaries were distributed via a web-based survey, in which experts completed
the ADDI, estimated the degree of disease damage and disease activity using a 10-point
PGA-damage and PGA-activity, respectively, and could provide comments. The distribution
of cases followed the ‘observer-nested-within-subject’ design, meaning that a large group
of experts all scored a subset of the cases.11 Each group of four experts scored 10 cases
each, a minimum of three doctors was needed per group to calculate the ICC. Additional
experts were asked to complete the survey when necessary. An equal proportion of adult
and paediatric physicians was ensured in each participant group. Furthermore, each group
contained four doctors from different countries and centres.
Definition of damage
Damage is defined as persistent or irreversible change in structure or function, which is
present for at least 6 months. Damage items should not be scored if they are attributed to
ongoing disease activity. Damage may be the result of prior disease activity, complications
of therapy or comorbid conditions that developed after the onset of AID signs and
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symptoms. If damage has been present for longer than 6 months, but later resolves, it should
still be scored in order to capture the damage that was present in the individual for that time
period. This definition can be found within in the ADDI in earlier versions of the damage
index.12
Statistical analysis
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Statistical analyses were performed in IBM SPSS Statistics V.21. The total score of the
ADDI is the sum of points given for all categories. The ICC was determined to assess
the reliability of the damage index as a whole, as well as for the eight categories and
all individual items. The ICC determined absolute agreement, for example, whether two
different physicians give the exact same score for a given patient, and considered single
measures, indicating reliability of a single observer.11 The ICC was also assessed for the
PGA-damage and the PGA-activity, in order to determine whether these measurements
would be sufficiently reliable to test construct validity. An ICC of 0.8 or higher was
considered indicative for excellent reliability.1117 Cronbach’s alpha was used to determine
possible redundancy of different items (eg, whether two items would score the same
damage). An interitem correlation of more than 0.7 was considered to indicate redundancy.18
A Spearman rank test was used to assess discriminant and convergent validity, correlating
the ADDI to PGA-activity and PGA-damage, respectively. A Spearman rank test with
r=0.1–0.3 was considered weak, r=0.3–0.5 was considered moderate and r>0.5 was
considered strong.19
Discussion on the items and definitions
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A small team (NMtH, ALJvD, JF) discussed all items with an ICC below 0.7. This
discussion encompassed possible explanations for a low score (eg, unclear definition of
an item or the lack of a growth chart hampering easy scoring of growth failure). Further,
based on experts’ comments and suggestions during the scoring, possibilities to improve the
item and/or definition were discussed. The initial and refined items were proposed to all
experts via a web-based survey and subsequently discussed in an open face-to-face meeting
at the Paediatric Rheumatology Congress in Athens (PReS 2017). Consensus was considered
achieved if more than 70% of experts agreed.

RESULTS
Pilot
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A pilot study with 15 paper cases was completed by four experts. This yielded a preliminary
ICC of 0.85 (95% CI 0.70 to 0.94), which implied that a minimum of 90 cases would be
needed for the validation of the ADDI. We therefore decided to assign 110 cases to the
experts.
Collection of cases
A total of 120 patients whose follow-up had been documented in the Eurofever Registry
were identified, and an additional 20 cases were submitted by non-European experts. By
selecting and combining case information, a total of 110 cases were compiled from these
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140 cases. The final paper clinical cases included 29 patients with CAPS, 27 with TRAPS,
29 with FMF and 25 with MKD.
Validation
In total, 37 of 44 participants responded. In 10 groups at least three participants responded,
which led to 100 cases that could be used for the analyses. Due to insufficient response in
one group, these 10 cases could not be used. Each item received a non-zero score (indicating
presence of that item) at least 18 times.
Intracluster correlation coefficient
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The ICC of the ADDI was 0.84 (95% CI 0.78 to 0.89). This indicates good inter-rater
reliability. The ICCs per disease, for different organ systems and the individual damage
items are shown in table 1. The highest ICC was found for the item ‘hearing loss’ (0.86,
95% CI 0.81 to 0.90) exceeding the overall ICC, the lowest ICC was found for the item
‘puberty delay’ (0.29, 95% CI 0.16 to 0.43).
Construct validity
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The ICCs of PGA-damage (0.75, 95% CI 0.67 to 0.81) and PGA-activity (0.62, 95% CI
0.52 to 0.71) were considered sufficiently reliable to determine construct validity. A strong
relation was found between the score of the ADDI and PGA-damage (Spearman’s r=0.92,
95% CI 0.88 to 0.95, p<0.001, see figure 1). This correlation coefficient indicates that an
increase in the ADDI score is strongly associated with an increase in the total estimated
damage. The relation between disease activity (PGA-activity) and the ADDI score was much
weaker (Spearman’s r=0.40, 95% CI 0.21 to 0.55, p<0.001, see figure 2), indicating that the
ADDI is not primarily driven by disease activity.
Interitem correlation
In order to assess whether items had too much overlap, interitem correlation was determined
using Cronbach’s alpha. Of specific interest was the interitem correlation between cognitive
impairment (mainly relating to adult patients or adolescents) and developmental delay
(mainly relating to paediatric patients), as the experts worried that these might have too
much overlap. The interitem correlation between cognitive impairment and developmental
delay was 0.66, indicating that there was minimal redundancy. All interitem correlation
matrixes can be found in online supplementary table 1a–e.
Comments from the experts
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The ADDI was considered a simple and easily applicable tool. The most important
feedback during the survey included comments and uncertainties about scoring, for example,
due to limited information in the case description (eg, the lack of growth charts to
completely assess growth failure), unclear definitions in the ADDI (eg, whether psychiatric
comorbidities are part of the item central nervous system (CNS) involvement), or doubts
about the severity of organ involvement (eg, severity of visual loss). A full overview of these
comments can be found in online supplementary table 2.
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Other important comments comprised item scoring (suggesting a higher/lower weighting),
or suggestions to refine item definitions. These suggestions were presented to all participants
using an online survey. The results of this survey were subsequently discussed in a
face-to-face meeting. Following this meeting, the maximum total score of the category
‘reproductive’ was limited to 2, in order to reduce sex differences in scoring of this
category. Furthermore, slight changes were made in the definitions for growth failure, CNS
involvement, joint restriction, puberty delay and serosal scarring (online supplementary table
2). The revised ADDI can be found in table 2.
All items were considered truthful, discriminative and feasible; however, doubts were raised
about the reliability and feasibility of the scoring of musculoskeletal pain as there is no
objective test to assess this. Despite that, it was considered that this particular item was
sufficiently valid and very important to patients; therefore it was kept as part of the ADDI.
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DISCUSSION
This validation study demonstrates that the ADDI is a reliable tool to measure damage
in the four main monogenic AIDs. Most items were considered clearly defined and easy
to score. Further, the ADDI correlated well with the estimated damage and was not
strongly influenced by disease activity, indicating good convergent and discriminant validity,
respectively. No significant overlap was found between items, therefore all items were
included in the final version of the ADDI. Some items were slightly refined, based on
comments provided by the clinical experts.
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This is the first validation of a disease damage index for AIDs. An ICC of 0.84 is
comparable to other damage indices for rheumatic diseases, such as the Juvenile Arthritis
Damage Index (ICC 0.85–0.97),20 Localized Scleroderma Skin Damage Index (ICC 0.99),21
Cutaneous Lupus Erythematosus Disease Area and Severity Index (ICC 0.86),22 Vasculitis
Damage Index (ICC 0.94)23 and Combined Damage Assessment (ICC 0.78).23
A key strength of this validation study is the participation of adult and paediatric experts
worldwide who all provided patient cases and scored the ADDI. This makes it plausible that
the ADDI can be used in clinical settings involving paediatric as well as adult patients with
FMF, CAPS, TRAPS or MKD. However, the fact that the AID experts scoring the cases
were also involved in the development of the ADDI and the collection of patient information
might have resulted in a relatively high ICC. Physicians with less knowledge of the tool or
AIDs in general might encounter more difficulties interpreting the damage items and scoring
the ADDI.
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Another strength of this study is the development of cases, which were based on actual
patient data while modifications were made to ensure a sufficient representation of all
damage items. The total of 110 cases is a large number for validation, given the rarity of
these diseases. However, the lack of validation in a real clinical setting is also a drawback
of this study. The modification of cases could have resulted in less realistic scenarios.
Additionally, scoring paper cases may be easier than applying ADDI in the clinical setting as
all the information is summarised and presented in a uniform way. On the other hand, due to
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the nature of cases (paper clinical instead of real patients) participants may have interpreted
data more ambiguously than they would in real life. Scoring anonymous cases, without
knowing the patients or being able to ask additional questions, is probably harder than in
daily practice. Indeed, comments of the participants reflected some of these difficulties they
experienced when assessing the paper cases.
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Some important issues could not yet be addressed due to the design of this validation study.
The responsiveness to change, that is, whether accrued damage over time is also reflected
in an increasing score of the ADDI in an individual patient, could not be determined.
A long-term observational study would be needed to measure responsiveness to change
and subsequently assess the minimal clinically important difference of the ADDI. Further,
convergent validity of the ADDI should preferentially include correlations with scores on
quality of life and functional ability, especially because the damage items in the ADDI had
been selected for their impact on patients’ lives. As the information about quality of life and
functional ability was lacking in the Eurofever Registry, this part of the construct validity
was impossible to assess. Moreover, ideally the discriminative validity of the ADDI should
be assessed by its correlation to a validated activity index, such as the Auto-Inflammatory
Disease Activity Index (AIDAI).2425 As we could not derive the AIDAI values from the
patient data, we used PGA-activity as a surrogate marker. However, the ICC of PGA-activity
was low with a broad CI, meaning that this estimate for activity as provided by the experts
was not a very reliable measure. This may be explained by the characteristics of these AIDs,
for example, episodes of febrile attacks with symptom-free periods in-between. Altogether,
a long-term prospective study assessing the ADDI, AIDAI and scores of quality of life and
functional ability in patients over time is needed to address the above-mentioned issues.
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Besides the strong correlation between the ADDI and PGA-damage, the ADDI also
moderately correlated to the PGA of disease activity. For a perfect discriminant validity,
there would be no correlation between the ADDI and an activity score. However, in this case
some degree of correlation is acceptable and probably unavoidable, since patients with more
disease activity over the years generally accrue more damage. Furthermore, some items
such as hearing loss may (initially) reflect both activity and damage. This overlap is partly
prevented by the criterion that an item should be present for at least 6 months to be scored as
a damage item. Therefore, disease activity has limited influence on the ADDI score.
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Although the overall ICC was >0.8, the ICC of some individual items was less than 0.6.
This could be explained by limited information provided in some of the paper cases, less
experience of adult rheumatologists with paediatric measures (eg, scoring of pubertal delay)
or the more subjective nature of some items (eg, musculoskeletal pain). Indeed, objective
items such as hearing loss, renal insufficiency and osteoporosis all had an individual ICC of
>0.8. As the overall ICC was good and the nature of the cases may be an important reason
for a lower ICC, items scoring less than 0.6 were deemed acceptable, although sometimes
with small alterations in the definition. A study testing the ADDI in real-life patients and
also by individuals not involved in its development would be needed to overcome the
above-mentioned issues.
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During the face-to-face meeting, it was suggested to omit musculoskeletal pain from the
ADDI, as it seems to be more subjective than the other items. Musculoskeletal pain, and
other less objectively scored items such as fatigue and headache, might better be captured by
patient-reported outcome measurements (PROM) in addition to the ADDI. A combination
with (items from) the juvenile autoinflammatory disease multidimensional assessment report
(JAIMAR) is worth considering.26 However, the JAIMAR is only validated on patients with
FMF. Because musculoskeletal pain was emphasised by the patient representatives during
the development phase of the ADDI as an important long-term disease burden in their daily
activities, it was decided to keep this item in the ADDI, at least until a composite damage
assessment including internationally validated PROMs is available.
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As we found a relatively high ICC for the PGA-damage among the experts, one could argue
that a detailed damage index is not necessary when the PGA is also reliable. However, we
would still recommend the use of a damage index, since the physicians scoring the ADDI
were considered experts in the area of AIDs, therefore their estimation of damage might
be more accurate than that of physicians with less experience. Second, even though the
estimates of PGA-damage might be reliable, an estimate of damage on a numerical scale
does not give transparent information on why a certain amount of damage was estimated
for a patient. The ADDI provides insight to the reasons why a certain level of damage is
scored for a patient. Third, the ADDI provides a useful aide memoire and systematic means
of collecting and quantifying damage, which is crucial to enable future comparisons between
different studies.
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Since damage prevention is one of the main purposes in the anti-inflammatory treatment
of AIDs, its reliable assessment is an important measure in clinical practice as well as
in therapeutic trials. As more information becomes available for the long-term outcomes
of AIDs, the ADDI will have to reflect these in a data-driven manner. So far, it can be
considered a reliable tool to assess disease damage for the four most commonly encountered
monogenic AIDs.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Correlation of the mean ADDI score and the mean score of damage (PGA-damage) per case,
assessed by at least three observers. Each dot represents a patient case. The line indicates
the correlation. ADDI, Autoinflammatory Disease Damage Index; PGA, Physician Global
Assessment.
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Figure 2.

Correlation of the mean ADDI score and the mean score of activity (PGA-activity) per case,
assessed by at least three observers. Each dot represents a patient case. The line indicates
the correlation. ADDI, Autoinflammatory Disease Damage Index; PGA, Physician Global
Assessment.
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Intraclass correlation coefficient (ICC) of the total ADDI score in all patients (overall), the ICC of the ADDI
in the four different diseases and separate ICCs for each category and damage item. Numbers in brackets
indicate the 95% CI
ICC (95% CI)
0.84 (0.78 to 0.89)

Overall
Per disease
CAPS

0.82 (0.71 to 0.91)

TRAPS

0.62 (0.39 to 0.80)

FMF

0.84 (0.72 to 0.92)

MKD

0.73 (0.55 to 0.86)

Per category
0.67 (0.59 to 0.76)

Reproductive

Author Manuscript

Sub/infertility

0.72 (0.63 to 0.79)

Amenorrhea

0.57 (0.46 to 0.67)
0.88 (0.84 to 0.92)

Renal/amyloidosis
Amyloidosis

0.76 (0.69 to 0.82)

Proteinuria

0.80 (0.73 to 0.85)

Renal insufficiency

0.84 (0.78 to 0.88)
0.54 (0.43 to 0.64)

Developmental
Growth failure

0.57 (0.46 to 0.67)

Puberty delay

0.29 (0.16 to 0.43)
0.64 (0.54 to 0.72)

Serosal
Serosal scarring

0.64 (0.54 to 0.72)
0.75 (0.67 to 0.81)

Neurological

Author Manuscript

Developmental delay

0.48 (0.37 to 0.60)

Cognitive impairment

0.54 (0.43 to 0.65)

Elevated ICP

0.65 (0.56 to 0.74)

CNS involvement

0.67 (0.58 to 0.75)
0.86 (0.82 to 0.90)

Ears
Hearing loss

0.86 (0.82 to 0.90)
0.74 (0.66 to 0.80)

Ocular
Ocular damage

0.74 (0.66 to 0.80)

Musculoskeletal

0.73 (0.64 to 0.80)

Author Manuscript

Joint restriction

0.52 (0.41 to 0.63)

Bone deformity

0.74 (0.66 to 0.81)

Osteoporosis

0.86 (0.81 to 0.90)

Musculoskeletal pain

0.47 (0.35 to 0.58)

ADDI, Autoinflammatory Disease Damage Index; CAPS, cryopyrin-associated periodic syndrome; CNS, central nervous system; FMF, familial
Mediterranean fever; ICP, intracranial pressure; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic
syndrome.
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Limited/extensive

1

3

4

3

Central nervous system involvement
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2
1
1

Osteoporosis

Musculoskeletal pain

The total ADDI score is the sum of the eight categories (maximum 27 points).

2

Bone deformity

Max 4

1/2/3

Max 3

1/2

Joint restriction

Musculoskeletal

Ocular involvement

Ocular

Hearing loss

Mild/moderate/severe

2

Elevated intracranial pressure

Max 2

3

Cognitive impairment

Ears

2

Max 6

1

Developmental delay

Neurological

Serosal scarring

Max 1

1

Serosal

2

Max 3

2/3

1

Puberty delay

Moderate/severe

Moderate/severe

2

2/3

Growth failure

Developmental

Renal insufficiency

Proteinuria

Amyloidosis

Max 6

1

Renal/amyloidosis

2

Amenorrhea

Max 2

Sub/infertility

Reproductive

Grading*

Points†

Author Manuscript

Damage item

Author Manuscript

Definitive ADDI including glossary of terms

Author Manuscript
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Hearing loss: moderate, hearing impairment without requirement of hearing aids or a cochlear implant; severe, hearing impairment requiring hearing aids or a cochlear implant.

Ocular involvement: mild, ocular damage without visual impairment; moderate, with visual impairment; severe, legal blindness.

Ann Rheum Dis. Author manuscript; available in PMC 2021 September 02.

Growth velocity over 6 months lower than the third percentile or −2 SD for age.

Crossing at least two centiles (5%, 10%, 25%, 50%, 75%, 90%, 95%) on growth chart.

•

•

Ocular involvement: Ocular damage (eg, optic nerve atrophy, elevated intraocular pressure or cataract) of better eye, documented by an ophthalmologist, with or without visual impairment.

Musculoskeletal pain: Non-inflammatory musculoskeletal pain impairing activities of daily living.

Joint restriction: Fixed limitation in the normal range of motion of joints affecting function, with or without destructive arthropathy or avascular necrosis.

Infertility: A disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse, not due to known disorders in the
unaffected partner.

Hearing loss: Sensorineural hearing impairment of better ear, confirmed by audiometry or another age-appropriate technique, or requirement of hearing aids or a cochlear implant.

For patients older than 18 years: Pathological short stature (eg, below third percentile or −2 SD for normal ethnic population).

Lower than the third percentile or −2 SD height for age.

•

Growth failure: Defined as the presence of at least two of the three features:

Elevated intracranial pressure: Signs and/or symptoms of elevated intracranial pressure supported by appropriate techniques#.

Developmental delay$: Failure to reach age-appropriate developmental milestones, including language/speech, motor, social/emotional, and cognitive milestones.

Cognitive impairment: Requirement of special education because of cognitive impairment or IQ below 70 as defined by neuropsychological assessment (eg, Wechsler Intelligence Scale for Children, WISC)
or other age-appropriate equivalents.

Central nervous system involvement: Focal deficits (gross and/or fine sensorimotor), diffuse deficits (eg, memory, behaviour), seizures and spinal cord symptoms. Neuropsychiatric disorders unrelated to the
disease should not be scored.

Bone deformity: Bone deformation or overgrowth on clinical examination and/or imaging studies.

Amyloidosis: Symptomatic amyloidosis confirmed by examination of tissue sections by Congo red dye or serum amyloid P component (SAP) scintigraphy.

Amenorrhea: Primary amenorrhea: absence of menarche at the age of 16 years or absence of menarche 5 years after the larche in a woman. Secondary amenorrhea: absence of the menses for six consecutive
months or more in a woman who previously had menstrual cycles.

Glossary of terms

ADDI, Autoinflammatory Disease Damage Index; Max, maximum.

Points are given when the item is present. For items with grading in severity, the lowest score is given for mild involvement and the highest for severe involvement. For each category, the score is limited to
a specific maximum.

†

4

3

Amyloidosis: limited, affecting one organ extensive, affecting more than one organ.

Renal insufficiency: moderate, glomerular filtration rate (GFR) between 15 and 60 mL/min/1.73 m2; severe, GFR <15 mL/min/1.73 m2, dialysis or transplantation.

2
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Grading: scoring depends on the severity of damage:

Author Manuscript

1

Author Manuscript

*

ter Haar et al.
Page 18

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

$Only for paediatric patients; #such as funduscopy, neuroimaging or lumbar cerebrospinal fluid (CSF) pressure measurement.

Serosal scarring: Symptomatic adhesions or fibrosis affecting pericardium, pleura, peritoneum and/or retroperitoneum, supported by imaging techniques, endoscopy or surgery.

Renal insufficiency: Glomerular filtration rate (GFR) of <60 mL/min/1.73 m2, dialysis or transplantation.

Puberty delay: A Tanner stage below −2 SDs for age or below the third percentile for age or any Tanner stage after pharmacological induction of puberty.

Proteinuria: Persistent urinary protein-to-creatinine ratio of >20 mg/mmol in the first morning void; and/or a daily protein excretion of >0.3 g/24 hours, or urine albumin-to-creatinine ratio of >15 mg/mmol.

Osteoporosis: Reduced bone mineral density with vertebral collapse and/or pathological fractures confirmed with imaging, which may include bone densitometry. Requires both evidence of decreased bone
density and fracture, ‘low bone density’ by itself is insufficient.

ter Haar et al.
Page 19

Ann Rheum Dis. Author manuscript; available in PMC 2021 September 02.

